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Recurrent respiratory papillomatosis (RRP) is caused by a
human papilloma virus (HPV). It is a rare, sometimes
debilitating disease compromising voice and airway. RRP
is characterized by a variable course of disease, potentially
leading to frequent annual surgical procedures, the number
of which may exceed a hundred during the life time. The
therapy focuses on surgical removal of the mucosal lesions
in order to keep the airway open and the voice satisfactory.
Till now, there is no curative therapy for the virus infection
in itself. As recurrent surgery alone has proven to be
insufﬁcient in many cases, adjuvant therapy is increasingly
being used. One of the mainstays of adjuvant therapy is the
administration of intralesional cidofovir (Vistide
).
Cidofovir is an antiviral agent, registered for the treat-
ment of cytomegalovirus (CMV) retinitis in patients with
AIDS. Since 1998 the drug has been used to treat patients
with RRP [1]. Cidofovir can be regarded as a prodrug. It
exerts the antiviral effect by decreasing the efﬁciency of
DNA transcription following incorporation into the grow-
ing DNA chain [2]. Its use has been advocated in cases of
papilloma refractive to repeated surgery, either due to its
spread, or to its recurrence rate. Some case reports and
series showed the effect of cidofovir treatment with few or
no side effects [3–8]. The only prospective double-blind
randomized controlled trail showed a signiﬁcant improve-
ment in the Derkay severity score between the cidofovir
and placebo group but failed to show signiﬁcant beneﬁt in
number of procedures performed [9].
On January 31 2011, an alarming news was communi-
cated by Gilead (the producer of cidofovir) concerning
very serious side effects of its off-label use [10]. The
warning included reports on nephrotoxicity, neutropenia,
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DOI 10.1007/s00405-011-1804-7oncogenicity and even some fatalities. The manufacturer
emphasized that cidofovir is formulated for intravenous
infusion only and the indication is CMV infection of AIDS
patients. The manufacturer did not specify the severity of
the reported complications, neither the off-label indication
of the drug nor its way of administration. Unfortunately, up
to the end of May 2011 the above mentioned communi-
cation was not received by the laryngologists in most
countries.
The warning caused a lot of discussion within the
European Laryngological Society (ELS). The ELS (having
[350 active members) is the main laryngological organi-
zation in Europe, representing laryngologists from more
than 55 countries on all continents (http://www.elsoc.org).
The ELS has taken its responsibility and initiated a
research project on the side effects of off-label use of ci-
dofovir in RRP patients.
The purpose of such a study is to determine whether
there are known nephrotoxic, neutropenic, or oncogenic
side effects after having used intralesional cidofovir in
patients with RRP. Facts are needed to decide whether or
not intralesional use of cidofovir in the larynx is safe or
not. Side effects might be dose dependent, and occur as a
consequence of the number of administrations, the interval
between applications or the cumulative dose. To determine
the aforementioned, a multicenter retrospective analysis
has been initiated among members of the ELS for which,
among others, all members of its Scientiﬁc Council have
been approached.
Parallel to the retrospective study we are conducting an
update on reported side effects in the literature.
Reports of the studies will be submitted for publication
in the ofﬁcial journal of the ELS, the European Archives of
Otorhinolaryngology, Head and Neck Surgery.
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